The European Union and its Member States have announced a substantial contribution of over €750 million (more than $800 million) to the African Vaccines Manufacturing Accelerator (AVMA), launched on 20th June in Paris. The European Union Commission Press Release says that the investment includes nearly €220 million ($233 million) from the EU budget. Developed by Gavi, the Vaccine Alliance, alongside Africa Centres for Disease Control and Prevention (Africa CDC), the AVMA aims to boost the predictability of demand for Africa-produced vaccines.
This initiative will support sustainable growth in Africa’s vaccine manufacturing capacity, aligning with the African Union’s goal to produce the majority of vaccines needed by African nations locally. Team Europe, comprising the EU and Member States France, Germany, Ireland, Italy, and Luxembourg, is the largest contributor to this effort. The AVMA is set to purchase over 800 million doses produced in Africa over the next decade, enhancing pandemic preparedness, response, and global health security.
This effort complements the existing MAV+ initiative, furthering health financing and promoting social health protection across the continent.
